Nature Biotechnology: Septerna – making another run on GPCRs
Read More
Septerna 250 East Grand Avenue, Suite 65 South San Francisco, CA 94080
Posts by cory
Septerna Announces Novel GPCR-targeted Program Acquired by Vertex
Read More
Septerna Bolsters Leadership Team as the Company Advances its Multi-Product Pipeline Toward Clinical Studies
Read More
Septerna Secures $150 Million in Series B Financing to Advance Pipeline of Novel GPCR-targeted Medicines
Read More
Nature Reviews Drug Discovery: Setting GPCRs Free
Read More
Biopharma Dive: GPCR-targeting drugs: A renewed focus on a ubiquitous group of proteins
Read More
BioSpace: Top Life Sciences Startups to Watch in 2023
Read More
Septerna Announces the Formation of a Cross-Functional Scientific and Drug Discovery Advisory Board
Read More
Septerna Appoints Jeffrey Finer, MD, PhD, as Chief Executive Officer
Read More